Healthcare Services

Hormone Refractory Prostate Cancer Market Growth Prospects 2026–2030 with Innovation Trends and Competitive Landscape

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Hormone Refractory Prostate Cancer Market Across 2026–2030?

The market size for hormone refractory prostate cancer has seen rapid expansion in recent years. It is anticipated to grow from $8.12 billion in 2025 to $8.95 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.2%. This historical growth can be linked to the increasing incidence of advanced prostate cancer, the widespread adoption of androgen deprivation therapy, the enhanced availability of chemotherapy agents, the growing utilization of PSA-based disease monitoring, and the expansion of oncology care infrastructure.

The market for hormone refractory prostate cancer is anticipated to experience substantial expansion in the coming years. Projections indicate this market will reach a valuation of $13.09 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.0%. This projected growth during the forecast period is fueled by several factors, including the escalating development of targeted therapies, heightened clinical trial engagement in castration-resistant prostate cancer, a surging demand for individualized oncology care, the broadening scope of immuno-oncology pipelines, and increased financial investment in cancer treatments within healthcare. Key trends expected during this period encompass the wider embrace of precision oncology treatments, the growing application of combination drug regimens, greater incorporation of biomarker-guided treatment choices, the broadening of immunotherapy uses in advanced prostate cancer cases, and an intensified emphasis on tailored patient treatment plans.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25786&type=smp

What Primary Drivers Are Shaping The Development Of The Hormone Refractory Prostate Cancer Market?

Increased funding for cancer research is anticipated to drive the expansion of the hormone-refractory prostate cancer market in the future. Such investment encompasses financial and resource backing aimed at progressing novel methods for cancer detection, treatment, and prevention. The escalation in cancer research funding stems from the increasing worldwide prevalence of cancer, necessitating more potent and precise therapeutic options. Funding dedicated to cancer research fosters innovation in the treatment of hormone-refractory prostate cancer by facilitating cutting-edge therapies like radioligand treatments and hormone inhibitors. Additionally, it finances clinical trials and studies on biomarkers, thereby improving treatment accuracy and results. As an illustration, in August 2024, the Cancer Research Institute (CRI), a US-based nonprofit organization focused on promoting immunotherapy research, allocated approximately $22.8 million during the 2023–2024 fiscal year, supporting 64 new grants for researchers affiliated with 42 institutions spanning seven countries. Consequently, the expanding investment in cancer research is fueling the expansion of the hormone-refractory prostate cancer market.

What Segmentation Levels Are Considered In The Hormone Refractory Prostate Cancer Market?

The hormone refractory prostate cancer market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegments:

1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Estramustin

2) By Hormonal Therapy: Anti-Androgens, CYP17 Inhibitors, LHRH Agonists, LHRH Antagonists

3) By Immunotherapy: Cancer Vaccines, Immune Checkpoint Inhibitors, Adoptive Cell Therapy

4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Radionuclide Therapy

5) By Surgery: Radical Prostatectomy, Orchiectomy, Transurethral Resection Of The Prostate (TURP)

Which Upcoming Trends Are Expected To Influence The Hormone Refractory Prostate Cancer Market?

Leading companies in the hormone-refractory prostate cancer market are concentrating on developing advanced therapies, such as intravenous radioligand therapy, to enhance survival rates for patients with resistant forms of the disease. Intravenous radioligand therapy is a precise treatment that employs radioactive molecules linked to ligands to identify and attach to cancer-specific markers. It internally eradicates cancer cells while safeguarding surrounding healthy tissue. For instance, in March 2025, Novartis AG, a pharmaceutical corporation headquartered in Switzerland, introduced Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which gained approval from the Food and Drug Administration (FDA). This therapy is intended for earlier administration in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously received treatment with an androgen receptor pathway inhibitor (ARPI) and are suitable for delaying chemotherapy. The expanded indication, informed by the Phase III PSMAfore trial, approximately triples the eligible patient population and revealed that Pluvicto lowered the risk of radiographic progression or death by 59% and more than doubled median radiographic progression-free survival compared to a change in ARPI. Pluvicto stands as the first targeted radioligand therapy authorized for use before chemotherapy in this context, presenting a fresh treatment avenue that delays disease progression alongside a favorable safety profile.

Which Leading Firms Are Contributing To The Growth Of The Hormone Refractory Prostate Cancer Market?

Major companies operating in the hormone refractory prostate cancer market are Pfizer Inc, Johnson And Johnson, F Hoffmann La Roche Ltd, Merck And Co Inc, AbbVie Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Novartis AG, AstraZeneca Plc, Eli Lilly And Company, Amgen Inc, Astellas Pharma Inc, Ipsen Pharma, Exelixis Inc, Orion Corporation, Lantheus Holdings Inc, Clovis Oncology Inc, Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC, Janssen Pharmaceuticals Inc, Bayer Healthcare Pharmaceuticals Inc

Read the full hormone refractory prostate cancer market report here:

https://www.thebusinessresearchcompany.com/report/hormone-refractory-prostate-cancer-global-market-report

How Does The Hormone Refractory Prostate Cancer Market Perform Across Major Global Regions?

North America was the largest region in the hormone-refractory prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormone refractory prostate cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Hormone Refractory Prostate Cancer Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25786&type=smp

Browse Through More Reports Similar to the Global Hormone Refractory Prostate Cancer Market 2026, By The Business Research Company

Prostate Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Benign Prostatic Hyperplasia Bph Treatment Devices And Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-bph-treatment-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795